Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
DARPA to sponsor evaluation of CX717 in a new study in shift work
July 24th, 2005
Cortex Pharmaceuticals, Inc., (COR) announced that the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense is sponsoring a new CX717 study. Results from this study could help confirm and extend the positive findings with CX717 from the recently completed sleep deprivation study. The new study will evaluate the cognitive performance and objective alerting effects of CX717 utilizing a simulated night shift work paradigm. Volunteers will undergo 4 nights of simulated shift work during which they will be "on shift" (high work load) from 11:00 PM to 7:00 AM. The volunteers will also be restricted to only 4 hours of recovery...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
